Peptide-20

General Information


DRACP ID  DRACP00244

Peptide Name   Peptide-20

Sequence  CSSRTMHHC

Sequence Length  9

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HL-60 Adult acute myeloid leukemia; Acute myeloid leukemia Leukemia 90% viablity=100 µM MTT assay 48 h 1
MDA-MB-231 Breast adenocarcinoma Carcinoma 55% viablity=100 µM MTT assay 48 h 1
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma 50% viablity=100 µM MTT assay 48 h 1
B16-F10 Mouse melanoma Carcinoma 50% viablity=100 µM MTT assay 48 h 1
A2058 Amelanotic melanoma Carcinoma 30% viablity=100 µM MTT assay 48 h 1
SK-MEL-25 Melanoma Carcinoma 55-60% viablity=100 µM MTT assay 48 h 1
SK-MEL-28 Cutaneous melanoma Carcinoma 35-40% viablity=100 µM MTT assay 48 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  cadherin constituent at the tumor cell surface

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00244

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C39H64N16O13S3

Absent amino acids  ADEFGIKLNPQVWY

Common amino acids  CHS

Mass  120409

Pl  8.25

Basic residues  3

Acidic residues  0

Hydrophobic residues  0

Net charge  3

Boman Index  -2870

Hydrophobicity  -70

Aliphatic Index  0

Half Life 
  Mammalian: 5.5 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  125

Absorbance 280nm  15.63

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 20802991

Title  A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity

Doi 10.1007/s00109-010-0671-9

Year  2010

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.